Ebook-2019

Bispecific Antibody Therapeutics Market

(4th Edition), 2019-2030

PREPARED BY
ROOTS ANALYSIS

www.RootsAnalysis.com
BISPECIFIC ANTIBODY THERAPEUTICS MARKET (4TH EDITION), 2019-2030

PAGE 01

Roots Analysis

Overview

The first monoclonal antibody, Bispecific antibodies are a novel class

Orthoclone OKT3®, was approved in
1986 by the FDA. Since then, a
number of antibody therapeutics
(more than 100) have been marketed
for the treatment of patients
suffering from various disease
indications, primarily malignant
tumors and other rare disorders.
Despite the success, these drugs are
associated with several limitations,
such as increased patient resistance
and a general lack of understanding
of in vivo mechanisms of action. The
aforementioned challenges and
impending patent expiries of some of
the blockbuster monoclonal
antibodies have compelled the
researchers and pharmaceutical
companies to redesign these drugs
and / or find new analogues. To
further improve the specificity,
efficacy and safety of monoclonal
antibodies, the focus has gradually
shifted towards the development of
next generation recombinant
antibodies, such as antibody-drug
conjugates (ADCs), bispecific and
multispecific antibodies, and
antibody fragments and antibody-like
proteins (ALPs).
of antibody therapeutics that act by
simultaneously binding two separate
and unique antigens (or different
epitopes of the same antigen). The
primary mechanism of action of these
therapeutics involves redirection of
immune effector cells for effective
killing of cancer cells by antibody-
dependent cell mediated cytotoxicity
(ADCC) and other cytotoxic
mechanisms, such as antibody
dependent cellular phagocytosis
(ADCP) and complement dependent
cytotoxicity (CDC). Having unique
biological and pharmacological
properties, as well as their
availability in different formats,
bispecific antibodies have emerged as
promising agents for therapeutic use.
Advancements related to protein and
antibody engineering techniques have
led to the production of close to 50
new formats in the recent years.
EXAMPLE INSIGHTS
PAGE 02

57%
stock maturity

38%
finance growth
 Roots Analysis

About Us

ROOTS ANALYSIS
We provide market research and consulting in the pharmaceutical industry.
Focussed on providing an informed and impartial view on key issues facing
the industry, our research is primarily driven by an in-depth analysis
covering the following parameters:
Technology evolution
Research and development
Existing market landscape
Future Commercial potential
Regulatory concerns
Regional growth drivers
Risks and opportunities
We specialise in analysing areas which have lacked quality research so far
or require more focussed understanding within the broader industry. All
our reports are structured in a way to enable the reader develop a
thorough perspective on the given subject. Apart from writing reports on
identified areas, we also provide bespoke research / consulting services
dedicated to serve our clients in the best possible way.

Usefull Links-
- https://www.rootsanalysis.com/
- https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html